JP2024532726A5 - - Google Patents
Info
- Publication number
- JP2024532726A5 JP2024532726A5 JP2024507076A JP2024507076A JP2024532726A5 JP 2024532726 A5 JP2024532726 A5 JP 2024532726A5 JP 2024507076 A JP2024507076 A JP 2024507076A JP 2024507076 A JP2024507076 A JP 2024507076A JP 2024532726 A5 JP2024532726 A5 JP 2024532726A5
- Authority
- JP
- Japan
- Prior art keywords
- cancer
- monoclonal antibody
- seq
- vedotin
- igsf8
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2020108129 | 2020-08-10 | ||
| CNPCT/CN2021/111469 | 2021-08-09 | ||
| PCT/CN2021/111469 WO2022033419A2 (en) | 2020-08-10 | 2021-08-09 | Compositions and methods for treating autoimmune diseases and cancers by targeting igsf8 |
| PCT/US2022/039838 WO2023018722A2 (en) | 2020-08-10 | 2022-08-09 | Compositions and methods for treating autoimmune diseases and cancers by targeting igsf8 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024532726A JP2024532726A (ja) | 2024-09-10 |
| JP2024532726A5 true JP2024532726A5 (https=) | 2025-08-19 |
Family
ID=77431086
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023509663A Active JP7832177B2 (ja) | 2020-08-10 | 2021-08-09 | Ｉｇｓｆ８を標的化することによる自己免疫疾患および癌を治療するための組成物および方法 |
| JP2024507076A Pending JP2024532726A (ja) | 2020-08-10 | 2022-08-09 | Ｉｇｓｆ８を標的化することによる自己免疫疾患および癌を治療するための組成物および方法 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023509663A Active JP7832177B2 (ja) | 2020-08-10 | 2021-08-09 | Ｉｇｓｆ８を標的化することによる自己免疫疾患および癌を治療するための組成物および方法 |
Country Status (10)
| Country | Link |
|---|---|
| US (2) | US20230303695A1 (https=) |
| EP (2) | EP4192866A2 (https=) |
| JP (2) | JP7832177B2 (https=) |
| KR (2) | KR20230077722A (https=) |
| CN (2) | CN116724051A (https=) |
| AU (2) | AU2021325225A1 (https=) |
| CA (2) | CA3188996A1 (https=) |
| IL (2) | IL300537A (https=) |
| MX (2) | MX2023001707A (https=) |
| WO (2) | WO2022033419A2 (https=) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2020232247A1 (en) | 2019-05-14 | 2020-11-19 | Provention Bio, Inc. | Methods and compositions for preventing type 1 diabetes |
| IL298999A (en) | 2020-06-11 | 2023-02-01 | Provention Bio Inc | Methods and compositions for the prevention of type 1 diabetes |
| CN116724051A (zh) * | 2020-08-10 | 2023-09-08 | 上海寻百会生物技术有限公司 | 用于通过靶向igsf8来治疗自身免疫性疾病和癌症的组合物和方法 |
| JP2024520444A (ja) | 2021-05-24 | 2024-05-24 | プロヴェンション・バイオ・インコーポレイテッド | １型糖尿病を治療するための方法 |
| WO2025251015A1 (en) * | 2024-05-30 | 2025-12-04 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Pan-gi norovirus monoclonal antibody and its use |
Family Cites Families (46)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| GB8823869D0 (en) | 1988-10-12 | 1988-11-16 | Medical Res Council | Production of antibodies |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| US6713610B1 (en) | 1990-01-12 | 2004-03-30 | Raju Kucherlapati | Human antibodies derived from immunized xenomice |
| US6673986B1 (en) | 1990-01-12 | 2004-01-06 | Abgenix, Inc. | Generation of xenogeneic antibodies |
| US5874299A (en) | 1990-08-29 | 1999-02-23 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| US6255458B1 (en) | 1990-08-29 | 2001-07-03 | Genpharm International | High affinity human antibodies and human antibodies against digoxin |
| US5877397A (en) | 1990-08-29 | 1999-03-02 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
| US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
| US6300129B1 (en) | 1990-08-29 | 2001-10-09 | Genpharm International | Transgenic non-human animals for producing heterologous antibodies |
| US6342220B1 (en) | 1997-08-25 | 2002-01-29 | Genentech, Inc. | Agonist antibodies |
| CA2348292A1 (en) | 1998-10-30 | 2000-05-11 | Takeda Chemical Industries, Ltd. | Betacellulin protein-containing preparation |
| US6900292B2 (en) | 2001-08-17 | 2005-05-31 | Lee-Hwei K. Sun | Fc fusion proteins of human erythropoietin with increased biological activities |
| DK1638941T3 (da) | 2003-05-22 | 2010-10-11 | Abbott Lab | Indazol-, benzisoxazol- og benzisothiazolkinaseinhibitorer |
| CA2541651C (en) | 2003-10-22 | 2011-05-24 | Keck Graduate Institute | Methods of synthesizing heteromultimeric polypeptides in yeast using a haploid mating strategy |
| TWI380996B (zh) | 2004-09-17 | 2013-01-01 | Hoffmann La Roche | 抗ｏｘ４０ｌ抗體 |
| WO2006076288A2 (en) | 2005-01-11 | 2006-07-20 | Five Prime Therapeutics, Inc. | Dna constructs for long-term expression of intravascularly injected naked dna |
| CA2589895A1 (en) | 2005-01-27 | 2006-08-03 | Five Prime Therapeutics, Inc. | Leader sequences for directing secretion of polypeptides and methods for production thereof |
| PT2343320T (pt) | 2005-03-25 | 2018-01-23 | Gitr Inc | Anticorpos anti-gitr e as suas utilizações |
| PL1879573T3 (pl) | 2005-05-10 | 2013-05-31 | Incyte Holdings Corp | Modulatory 2,3-dioksygenazy indoloaminy i sposoby ich zastosowania |
| PT1907424E (pt) | 2005-07-01 | 2015-10-09 | Squibb & Sons Llc | Anticorpos monoclonais humanos para o ligando 1 de morte programada (pd-l1) |
| US8450351B2 (en) | 2005-12-20 | 2013-05-28 | Incyte Corporation | N-hydroxyamidinoheterocycles as modulators of indoleamine 2,3-dioxygenase |
| WO2008036642A2 (en) | 2006-09-19 | 2008-03-27 | Incyte Corporation | N-hydroxyamidinoheterocycles as modulators of indoleamine 2,3-dioxygenase |
| CL2007002650A1 (es) | 2006-09-19 | 2008-02-08 | Incyte Corp | Compuestos derivados de heterociclo n-hidroxiamino; composicion farmaceutica, util para tratar cancer, infecciones virales y desordenes neurodegenerativos entre otras. |
| EP1987839A1 (en) | 2007-04-30 | 2008-11-05 | I.N.S.E.R.M. Institut National de la Sante et de la Recherche Medicale | Cytotoxic anti-LAG-3 monoclonal antibody and its use in the treatment or prevention of organ transplant rejection and autoimmune disease |
| US8591886B2 (en) | 2007-07-12 | 2013-11-26 | Gitr, Inc. | Combination therapies employing GITR binding molecules |
| US7981415B2 (en) | 2007-09-07 | 2011-07-19 | Cisthera, Inc. | Humanized PAI-1 antibodies |
| EP2044949A1 (en) | 2007-10-05 | 2009-04-08 | Immutep | Use of recombinant lag-3 or the derivatives thereof for eliciting monocyte immune response |
| US10047066B2 (en) | 2007-11-30 | 2018-08-14 | Newlink Genetics Corporation | IDO inhibitors |
| AR072999A1 (es) | 2008-08-11 | 2010-10-06 | Medarex Inc | Anticuerpos humanos que se unen al gen 3 de activacion linfocitaria (lag-3) y los usos de estos |
| EP3255060A1 (en) | 2008-12-09 | 2017-12-13 | F. Hoffmann-La Roche AG | Anti-pd-l1 antibodies and their use to enhance t-cell function |
| KR101790802B1 (ko) | 2009-09-03 | 2017-10-27 | 머크 샤프 앤드 돔 코포레이션 | 항-ｇｉｔｒ 항체 |
| CA2796055A1 (en) * | 2010-04-15 | 2011-10-20 | Amgen Inc. | Human fgf receptor and .beta.-klotho binding proteins |
| MX337040B (es) | 2010-09-09 | 2016-02-09 | Pfizer | Moleculas de union a 4-1bb. |
| NO2694640T3 (https=) | 2011-04-15 | 2018-03-17 | ||
| JP6072771B2 (ja) | 2011-04-20 | 2017-02-01 | メディミューン，エルエルシー | Ｂ７−ｈ１およびｐｄ−１に結合する抗体およびその他の分子 |
| KR101764096B1 (ko) | 2011-11-28 | 2017-08-02 | 메르크 파텐트 게엠베하 | 항-ｐｄ-ｌ1 항체 및 그의 용도 |
| RU2658603C2 (ru) | 2011-12-15 | 2018-06-21 | Ф.Хоффманн-Ля Рош Аг | Антитела против человеческого csf-1r и их применения |
| KR20140127855A (ko) | 2012-02-06 | 2014-11-04 | 제넨테크, 인크. | Csf1r 억제제를 사용하는 조성물 및 방법 |
| AR090263A1 (es) | 2012-03-08 | 2014-10-29 | Hoffmann La Roche | Terapia combinada de anticuerpos contra el csf-1r humano y las utilizaciones de la misma |
| RU2670743C9 (ru) | 2012-05-11 | 2018-12-19 | Файв Прайм Терапьютикс, Инк. | Способы лечения состояний антителами, которые связывают рецептор колониестимулирующего фактора 1 (csf1r) |
| UY34887A (es) | 2012-07-02 | 2013-12-31 | Bristol Myers Squibb Company Una Corporacion Del Estado De Delaware | Optimización de anticuerpos que se fijan al gen de activación de linfocitos 3 (lag-3) y sus usos |
| CN107759690A (zh) | 2012-08-31 | 2018-03-06 | 戊瑞治疗有限公司 | 用结合群落刺激因子1受体(csf1r)的抗体治疗病状的方法 |
| TW201605896A (zh) | 2013-08-30 | 2016-02-16 | 安美基股份有限公司 | Gitr抗原結合蛋白 |
| KR20220151161A (ko) * | 2019-12-25 | 2022-11-14 | 상하이 엑스비에이치 바이오테크놀로지 씨오., 엘티디. | Igsf8의 표적화에 의해 자가면역 질환 및 암을 치료하기 위한 조성물 및 방법 |
| CN116724051A (zh) * | 2020-08-10 | 2023-09-08 | 上海寻百会生物技术有限公司 | 用于通过靶向igsf8来治疗自身免疫性疾病和癌症的组合物和方法 |
-
2021
- 2021-08-09 CN CN202180069002.4A patent/CN116724051A/zh active Pending
- 2021-08-09 IL IL300537A patent/IL300537A/en unknown
- 2021-08-09 KR KR1020237008022A patent/KR20230077722A/ko active Pending
- 2021-08-09 EP EP21758306.1A patent/EP4192866A2/en active Pending
- 2021-08-09 MX MX2023001707A patent/MX2023001707A/es unknown
- 2021-08-09 WO PCT/CN2021/111469 patent/WO2022033419A2/en not_active Ceased
- 2021-08-09 CA CA3188996A patent/CA3188996A1/en active Pending
- 2021-08-09 JP JP2023509663A patent/JP7832177B2/ja active Active
- 2021-08-09 US US18/020,447 patent/US20230303695A1/en active Pending
- 2021-08-09 AU AU2021325225A patent/AU2021325225A1/en active Pending
-
2022
- 2022-08-09 CN CN202280063856.6A patent/CN118660906A/zh active Pending
- 2022-08-09 US US18/682,489 patent/US20240343798A1/en active Pending
- 2022-08-09 MX MX2024001844A patent/MX2024001844A/es unknown
- 2022-08-09 WO PCT/US2022/039838 patent/WO2023018722A2/en not_active Ceased
- 2022-08-09 EP EP22856507.3A patent/EP4384551A4/en active Pending
- 2022-08-09 IL IL310534A patent/IL310534A/en unknown
- 2022-08-09 JP JP2024507076A patent/JP2024532726A/ja active Pending
- 2022-08-09 AU AU2022325756A patent/AU2022325756A1/en active Pending
- 2022-08-09 CA CA3228575A patent/CA3228575A1/en active Pending
- 2022-08-09 KR KR1020247007398A patent/KR20240044464A/ko active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US11942149B2 (en) | Bispecific binding molecules that are capable of binding CD137 and tumor antigens, and uses thereof | |
| JP2024532726A5 (https=) | ||
| US12527838B2 (en) | Combination therapies comprising an agent that blocks the interaction between CD47 and SIRPα for treating gastric or gastroesphageal junction cancel | |
| Singh et al. | Monoclonal antibodies: a review | |
| US20210371544A1 (en) | Low-viscosity antigen binding proteins and methods of making them | |
| US20250171558A1 (en) | HUMAN IgG Fc DOMAIN VARIANTS WITH IMPROVED EFFECTOR FUNCTION | |
| JP2023537131A5 (https=) | ||
| AU2018290272A1 (en) | Heterodimeric bispecific antibodies | |
| JP2022191210A5 (https=) | ||
| JP2017522384A5 (https=) | ||
| US12098214B2 (en) | Combination therapies for treating cancer | |
| JP2024508886A5 (https=) | ||
| US20230094162A1 (en) | Cd137 binding molecules and uses thereof | |
| JP2023535842A5 (https=) | ||
| WO2016179472A2 (en) | Modulation of natural killer cell tolerance | |
| WO2025252164A1 (zh) | 抗dll3和b7-h3的双抗药物偶联物 | |
| AU2025205081A1 (en) | HUMAN IgG Fc DOMAIN VARIANTS WITH IMPROVED EFFECTOR FUNCTION | |
| OA19914A (en) | Human IgG Fc domain variants with improved effector function. | |
| EA046873B1 (ru) | Cd137-связывающие молекулы и варианты их применения | |
| EA045802B1 (ru) | ВАРИАНТЫ ДОМЕНА Fc IgG ЧЕЛОВЕКА С УЛУЧШЕННОЙ ЭФФЕКТОРНОЙ ФУНКЦИЕЙ | |
| NZ743923B2 (en) | Chimeric proteins and methods of immunotherapy |